Print Page | Close Window

Investor Relations Home

Profile
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 60 independent distributors into over 100 countries.
Stock Quote
IRIX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$4.49
Change (%) Stock is Down 0.19 (4.06%)
Volume9,309
Data as of 03/18/19 3:29 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
03/06/19IRIDEX to Present at the 31st Annual Roth Conference
MOUNTAIN VIEW, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to present at the upcoming 31st Annual Roth Conference in Orange County, CA. Management is scheduled to present on Tuesday, March 19, 2019 at 9:00 AM PT.  Interested parties may access a live and archived webcast of the presentation at www.IRIDEX.com. About IRIDEX IRIDEX Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and ve... 
Printer Friendly Version
03/05/19IRIDEX Announces 2018 Fourth Quarter and Full Year Financial Results
MOUNTAIN VIEW, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended December 29, 2018. Fourth Quarter Highlights Cyclo G6® product revenue increased approximately 16% year-over-year Shipped a record 12,300 Cyclo G6 probes Shipped 122 Cyclo G6 Glaucoma Laser Systems Revenue of $11.5 million, a 12% increase year-over-year “I am pleased with the accomplishments of our team in 2018.... 
Printer Friendly Version
02/26/19IRIDEX to Report Fourth Quarter and 2018 Financial Results on March 5, 2019
MOUNTAIN VIEW, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the fourth quarter and full year 2018 after the close of trading on Tuesday, March 5, 2019.  The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for ... 
Printer Friendly Version
02/12/19IRIDEX Announces Resolution of its Dispute with Quantel Medical
MOUNTAIN VIEW, Calif., Feb. 12, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has resolved its differences with Quantel Medical, S.A., Quantel USA, Inc., and Quantel, S.A. (collectively, “Quantel”) in its lawsuit filed against Quantel in the U.S. District Court for the Northern District of California. IRIDEX dismissed the lawsuit it had filed in January 2018, alleging that Quantel products infringed IRIDEX’s U.S. Patent No. 7,771,417, that Quantel breached ... 
Printer Friendly Version
Primary IR Contact
Lynn Lewis or Leigh Salvo
Phone: (415) 937-5404
E-mail: investors@iridex.com


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.